

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number  09/776533	Continuation of 08/823,999
		Filing Date	February 7, 2001
		First Named Inventor	Campbell Rogers
		Group Art Unit	
Examiner Name			
Sheet 1 of 7	Attorney Docket Number	MIT 7501 CON	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
RG		4,244,946		Rivier et al.	01-13-1981	_____
ME		4,305,872		Johnston et al.	12-15-1981	_____
ME		4,316,891		Guillemin et al.	02-23-1982	_____
ME		4,629,784		Stammer	12-16-1986	_____
ME		4,792,525		Ruoslahti et al.	12-20-1988	_____
ME		4,868,116		Morgan et al.	09-19-1989	_____
M		4,980,286		Morgan et al.	12-25-1990	_____
RG		5,324,510		Wegner et al.	06-28-1994	_____
ME		5,567,435		Hubbell et al.	10-22-1996	_____
ME		5,770,198		Coller et al	06-23-1998	_____

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office. <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
ME		WO	93/01286		Massachusetts Institute of Technology	01-21-1993		

Examine Signature	PHILLIP GAMBEL 9/3/01	Date Considered	
-------------------	-----------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	Continuation of 08/823,999		
		02/776533			
		Filing Date	February 7, 2001		
		First Named Inventor	Campbell Rogers		
		Group Art Unit			
Examiner Name					
Sheet	2	of	7	Attorney Docket Number	MIT 7501 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
PC		AGRAWAL, et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," <i>Proc. Natl. Acad. Sci. USA</i> 85(19):7079-7083 (1988).	
		ALBELDA, et al., "Adhesion molecules and inflammatory injury," <i>FASEB J</i> 8:504-512 (1994).	
		ALTIERI, et al., "Oligospecificity of the Cellular Adhesion Receptor MAC-1 Encompasses an Inducible Recognition Specificity for Fibrinogen," <i>J. Cell Biol.</i> 107(5):1893-1900 (1988).	
		ALTIERI, et al., "The Structural Motif Glycine 190-Valine 202 of the Fibrinogen Chain Interacts with CD11b/CD18 Integrin ( $\alpha_M\beta_2$ , Mac-1) and Promotes Leukocyte Adhesion," <i>J. Biol. Chem.</i> 268(3):1847-1853 (1993).	
		ANDERSON, et al., "Contributions of the Mac-1 Glycoprotein Family and Adherence-Dependent Granulocyte Functions: Structure-Function Assessments Employing Subunit-Specific Monoclonal Antibodies," <i>J. Immunol.</i> 137(1):15-27 (1986).	
		ASKEW, et al., "Molecular Recognition with Convergent Functional Groups. Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components," <i>J. Am. Chem. Soc.</i> 111(3):1082-1090 (1989).	
		AULT, et al., "Cross-Reaction of a Rat-Anti-Mouse Phagocyte-Specific Monoclonal Antibody (ANTI-Mac-1) with Human Monocytes and Natural Killer Cells," <i>J. Immunol.</i> 126(1):359-364 (1981).	
		BLUME, et al., "Triple helix formation by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter," <i>Nucl. Acids Res.</i> 20(7):1777-1784 (1992).	
		CLACKSON, et al., "Making antibody fragments using phage display libraries," <i>Nature</i> , 352(6336):624-688 (1991)	
M		COONEY, et al., "Site-Specific Oligonucleotide Binding Represses Transcription of the Human <i>c-myc</i> Gene <i>in Vitro</i> ," <i>Science</i> 241:456-459 (1988).	

Examiner's Signature	Philip G. Mael 2/7/01	Date Considered	
----------------------	-----------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Complete if Known			
		Application Number	Continuation of 08/823,999		
		09/776533			
		Filing Date	February 7, 2001		
		First Named Inventor	Campbell Rogers		
		Group Art Unit			
Examiner Name					
Sheet	3	of	7	Attorney Docket Number	MIT 7501 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
RG		CROOKE, "Progress toward oligonucleotide therapeutics: pharmacodynamic properties," <i>FASEB J.</i> 7(6):533-539 (1993).	
		DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <i>Nucl. Acids Res.</i> 19(9):2471-2476 (1991).	
		DIAMOND, et al., "The I Domain Is a Major Recognition Site on the Leukocyte Integrin Mac-1 (CD11b/CD18) for Four Distinct Adhesion Ligands," <i>J. Cell Bio.</i> 120(4):1031-1043 (1993).	
		DUVAL-VALENTIN, et al., "Specific inhibition of transcription of triple helix-forming oligonucleotides," <i>Proc. Natl. Acad. Sci. USA</i> 89(2):504-508 (1992).	
		EDGINGTON, "How sweet it is: selectin-mediating drugs," <i>Biotechnology</i> 10:383-389 (1992).	
		ELLINGTON, et al., "In vitro selection of RNA molecules that bind specific ligands," <i>Nature</i> 346(6287):818-822 (1990).	
		ELLINGTON, et al., "Selected in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures," <i>Nature</i> 355(6363):850-852 (1992).	
		FISCHMAN, et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease," <i>N. E. J. Med.</i> 331(8):496-501 (1994).	
		GENNETA & MAURO, "Abciximab: a new antiaggregant used in angioplasty," <i>Annals of Pharmacotherapy</i> 30:251-257 (1996).	
		GRIGORIEV, et al., "A Triple Helix-forming Oligonucleotide-Intercalator Conjugate Acts as a Transcriptional Repressor via Inhibition of NF KB Binding to Interleukin-2 Receptor $\alpha$ -Regulatory Sequence," <i>J. Biol. Chem.</i> 267(5):3389-3395 (1992).	

Examiner's Signature	PHILIP GAMBER 9/3/00	Date Considered	
----------------------	----------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	Continuation of 08/823,999		
		09/776 533			
		Filing Date	February 7, 2001		
		First Named Inventor	Campbell Rogers		
		Group Art Unit			
Examiner Name					
Sheet	4	of	7	Attorney Docket Number	MIT 7501 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		HOLT, et al., "An Oligomer Complementary to <i>c-myc</i> mRNA Inhibits Proliferation of HL-60 Promyelocytic Cells and Induces Differentiation," <i>Mol. Cell. Biol.</i> 8(2):963-973 (1988).	
	/	INOUE, et al., "Expression of Polymorphonuclear Leukocyte Adhesion Molecules and Its Clinical Significance in Patients Treated With Percutaneous Transluminal Coronary Angioplasty," <i>JACC</i> 28(5):1127-1133 (1996).	
		ITAKURA, et al., "Synthesis and Use of Synthetic Oligonucleotides," <i>Ann. Rev. Biochem.</i> 53:323-356 (1984).	
		KABAT, et al., <u>Sequences of Proteins of Immunological Interest</u> , 4th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD 1987) (Title page and Table of Contents only).	
		LEWIS, et al., "Automated site-directed drug design: the concept of spacer skeletons for primary structure generation," <i>Proc. R. Soc. Lond.</i> 236:125-140 and 141-162 (1989).	
		MAHER, et al., "Inhibition of DNA Binding Proteins by Oligonucleotide-Directed Triple Helix Formation," <i>Science</i> 245:725-730 (1989).	
		McKINLAY, et al., "Rational Design of Antiviral Agents," <i>Ann. Rev. Pharmacol. Toxicol.</i> 29: 111-122 (1989).	
		MERRIFEILD, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," <i>J. Am. Chem. Soc.</i> 85:2149-2154 (1963).	
		MICKELSON, et al., "Leukocyte Activation With Platelet Adhesion After Coronary Angioplasty: A Mechanism for Recurrent Disease?" <i>JACC</i> 28(2):345-353 (1996).	
		MULLIGAN, "The Basic Science of Gene Therapy," <i>Science</i> 260:926-932 (1993).	

Examiner's Signature	PHILIP GAMBEL 9/3/01	Date Considered	
----------------------	----------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	
				09/776533	
				Continuation of 08/823,999	
				Filing Date	
				February 7, 2001	
				First Named Inventor	
				Campbell Rogers	
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	
				MIT 7501 CON	
Sheet	5	of	7		

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
Mu		NARANG, et al., "Chemical Synthesis of Deoxyligonucleotides by the Modified Triester Method," <u>Methods Enzymol.</u> , Vol. 65, Chapter 61, pp. 610-620 (The Academic Press, New York 1980).	
		NEUMANN, et al., "Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty," <u>JACC</u> 27(4):819-24 (1996).	
		OFFENSPERGER, et. al., "In Vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides," <u>EMBO J.</u> 12(3):1257-1262 (1993).	
		ORSON, et al., "Oligonucleotide inhibition of IL2R $\alpha$ mRNA transcription by promoter region collinear triplex formation in lymphocytes," <u>Nucl. Acids Res.</u> 19(12):3435-3441 (1991).	
		PEPINE, et al., "A Controlled Trial of Coricosteroids to Prevent Restenosis After Coronary Angioplasty," <u>Circulation</u> 81(6):1753-1761 (1990).	
		PERRY, et al., "The Use of 3D Modelling Databases for Identifying Structure Activity Relationships," in <u>QSAR: Quantitative Structure-Activity Relationships in Drug Design</u> , (Fauchère, ed.) pp. 189-193 (Alan R. Liss, Inc. 1989).	
		PIETERSMA, et al., "Late Lumen Loss After Coronary Angioplasty Is Associated With the Activation Status of Circulating Phagocytes Before Treatment," <u>Circulation</u> 91(5):1320-1325 (1995).	
		POSTEL, et al., "Evidence that a triplex-forming oligodeoxyribonucleotide binds to the <i>c-myc</i> promoter in HeLa cells, thereby reducing <i>c-myc</i> mRNA levels," <u>Proc. Natl. Acad. Sci. USA</u> 88(18):8227-8231 (1991).	
		RICEVUTI, et al., "Role of granulocytes in endothelial injury in coronary heart disease in humans," <u>Atherosclerosis</u> 91:1-14 (1991).	
		RIPKA, "Computers picture the perfect drug," <u>New Scientist</u> 1617:54-57 (1988).	

Examiner's Signature	PHILIP GAMBEL	Date Considered	9/3/01
----------------------	---------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Complete if Known			
				Application Number		Continuation of 08/823,999	
				08/776533			
				Filing Date		February 7, 2001	
				First Named Inventor		Campbell Rogers	
				Group Art Unit			
Examiner Name							
Sheet	6	of	7	Attorney Docket Number		MIT 7501 CON	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
me		ROGERS, et al., "Endovascular Stent Design Dictates Experimental Restenosis and Thrombosis," <i>Circulation</i> 91(12):2995-3001 (1995).	
		ROGERS, et al., "Inhibition of Experimental Neointimal Hyperplasia and Thrombosis Depends on the Type of Vascular Injury and the Site of Drug Administration," <i>Circulation</i> 88(3):1215-1221 (1993).	
		ROGERS, et al., "Monocyte Recruitment and Neointimal Hyperplasia in Rabbits Coupled Inhibitory Effects of Heparin," <i>Art. Thromb. Vasc. Bio.</i> 16:1312-1318 (1996).	
		ROUVINEN, et al., "Computer and Drug Design," <i>Acta Pharmaceutica Fennica</i> 97:159-166 (1988).	
		SARIN, et al., "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates," <i>Proc. Natl. Acad. Sci. USA</i> 85(20):7448-7794 (1989).	
		SERRUYS, et al., "A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease," <i>N. E. J. Med.</i> 331(8):489-495 (1994).	
		SHAW, et al., "Modified deoxyligonucleotides stable to exonuclease degradation in serum," <i>Nucleic Acids Res.</i> 19(4):747-750 (1991).	
m		SIMON, et al., "7E3 Monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1," <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> 17(3):528-535 (1997).	
		SIMON, et al., "Monoclonal antibody directed against the platelet IIb/IIIa receptor cross-reacts with the leukocyte integrin mac-1 and blocks adhesion to fibrinogen and ICAM-1," <i>Circulation Abstract No. 0519 (Suppl 1) 92(8):1-110 (1995).</i>	
		SZOSTAK, "In Vitro Genetics," <i>TIBS</i> 17:89-93 (1992).	

Examiner's Signature	Peter G. Gabor a/3/02	Date Considered	
----------------------	-----------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Continuation of 08/823,999
		09/776533	
		Filing Date	February 7, 2001
		First Named Inventor	Campbell Rogers
		Group Art Unit	
Examiner Name			
Sheet	7	of	7
		Attorney Docket Number	MIT 7501 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
M		WICKSTROM, et al., "Human promyelocytic leukemia HL-60 cell proliferation and <i>c-myc</i> protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against <i>c-myc</i> mRNA," <i>Proc. Natl. Acad. Sci. USA</i> 85(4):1028-1032 (1988).	
		YOUNG, et al., "Triple helix formation inhibits transcription elongation <i>in vitro</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 88(22):10023-10026 (1991).	
		ZAMECNIK, et al., "Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA," <i>Proc. Natl. Acad. Sci.</i> , 83(12):4143-4146 (1986).	
		ZAMECNIK, et al., "Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide," <i>Proc. Natl. Acad. Sci. USA</i> 75(1):280-284 (1978).	
M		ZHU, et al., "Systemic Gene Expression After Intravenous DNA Delivery Into Adult Mice," <i>Science</i> 261:209-211 (1993).	

Examiner's Signature	Philip G. Miller 9/3/02	Date Considered	
----------------------	-------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.